Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome

• Published in: Advances in pharmacology (1990) Vol. 84; pp. 187 - 205
• Main Authors: Wanner, Vivian, Garcia Malo, Celia, Romero, Sofía, Cano-Pumarega, Irene, García-Borreguero, Diego
• Format: Journal Article
• Language: English
• Published: United States 2019
• Subjects: Analgesics, Opioid - therapeutic use; Dopamine Agents - therapeutic use; Dopamine Agonists - therapeutic use; Humans; Ligands; Restless Legs Syndrome - drug therapy; Restless Legs Syndrome - physiopathology; Sleep - physiology; Adenosine; Dopamine; Perampanel; Dipyridamole; Gabapentinoids; Opioids; Dopamine agonists; Glutamate; α2δ ligands
• ISSN: 1557-8925
• DOI: 10.1016/bs.apha.2019.02.003

Two types of drugs have been extensively investigated for the treatment of restless legs syndrome (RLS)/Willis-Ekbom disease (WED): dopamine agonists and α2δ ligands to the α2δ subunit of calcium channels. Comparative studies show that both classes of drugs are similarly effective in treating RLS symptoms over the short- and long-term. While dopamine agonists are more effective in treating periodic limb movements (PLMs), α2δ ligands are more effective in consolidating sleep. However, given the fact that dopamine agonists cause high rates of augmentation of symptoms, recent international guidelines recommend that whenever possible the initial treatment of choice should be an α2δ ligand. In fact, the most effective preventive strategy involves not using dopaminergic agents unless absolutely necessary. Indeed, should dopaminergic treatment be needed to handle the symptoms effectively, then it is recommended that the dopaminergic load be reduced by using the lowest effective dose for the shortest possible period of time. However, it must be taken into account that the only α2δ ligand approved for RLS/WED is gabapentin enacarbil, which is not yet available in Europe. Furthermore, recent studies have also reported on the efficacy of opioids as a second-line treatment of RLS/WED, following treatment failure with dopamine agonists. Recent guidelines have taken these new data into account and highlight that a low dose of an opioid (prolonged-release oxycodone or methadone) may be considered in patients with very severe augmentation of symptoms. Alternative non-dopaminergic treatment concepts based on glutamatergic and adenosinergic mechanisms are currently in development, and are likely to provide encouraging therapeutic alternatives.